---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-164515"
form_type: "8-K"
ticker: null
cik: "0001850079"
company_name: "Telesis Bio Inc."
filed_at: "2023-06-09T23:59:59+00:00"
generated_at: "2026-06-14T04:16:53.894168+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Telesis Bio closes $28M private placement of preferred stock and warrants; appoints Paul Meister to board

## Summary
- Initial gross proceeds of $28.0M from private placement of redeemable convertible preferred stock and warrants.
- Warrants could provide up to $46.2M in additional proceeds if cash exercised.
- Financing led by Novalis LifeSciences; includes participation from Northpond Ventures, BroadOak, and CEO affiliate M-185 Corp.
- Paul Meister, partner at Novalis LifeSciences, appointed to board effective June 5, 2023, expanding board from 7 to 8 directors.
- Proceeds to be used for general corporate purposes.

## SEC filing metadata
- accession: 0001193125-23-164515
- form_type: 8-K
- cik: 0001850079
- company_name: Telesis Bio Inc.
- filed_at: 2023-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.02, 3.03, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/d463439d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-164515
- JSON: https://secwatch.observer/filing/0001193125-23-164515.json
- Plain text: https://secwatch.observer/filing/0001193125-23-164515.txt

## Key facts
- Executive change
  Paul Meister was appointed as director at Telesis Bio Inc..
  - Action: appointed
  - Role: director
  source text: Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm
- Governance Changes
  Telesis Bio Inc.: Filed Certificate of Designation establishing Redeemable Convertible Preferred stock.
  - Change: charter amendment
  source text: Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the closing of the Private Placement, the Company filed with the Secretary of State of the State of Delaware the Certificate of Designation attached hereto as Exhibit 3.1 and incorporated herein by reference. The Certificate of Designation establishes and designates the Redeemable Convertible Preferred and the rights, preferences and privileges thereof.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850079/000119312523164515/0001193125-23-164515-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.